Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin for Early Symptoms of COVID-19
NCT04861298Completed
- Sponsor
- King Edward Medical University
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Quercetin with Standard of care (SOC) (2 arms). Primary endpoint: Testing negative for SARS-CoV-2 by RT-PCR with symptoms improvement at 14 days. Started Jan 2021; status: completed.
02
Drugs
quercetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04861298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861298.